The effects of ciclosporin in experimental glomerulosclerosis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The acute and chronic effects of daily, oral ciclosporin (CS) therapy (25 mg/kg) on proteinuria, blood pressure, renal function and histology were studied in rats subjected to unilateral nephrectomy and 3 weekly intraperitoneal injections of the aminonucleoside of puromycin (PAN). PAN therapy resulted in heavy proteinuria by week 4 which declined by weeks 8 and 16. When CS therapy was started several weeks after the last dose of PAN, acute, transient reductions in proteinuria and reversible rises in blood urea nitrogen (BUN) were observed. When CS or oil therapy was started with PAN and continued for 8 or 16 weeks, there were no differences in proteinuria; however, after 16 weeks, CS treated rats had significantly higher BUN levels [65 ± 11 (23.2 ± 3.9) vs. 41 ± 5 mg/dl (14.6 ± 1.8 mmol/l); p = 0.001], a higher percentage of sclerotic glomeruli (47 ± 7 vs. 28 ± 10%; p < 0.0001) and extensive interstitial fibrosis. There was a strong correlation between glomerulosclerosis and extent of interstitial fibrosis (r = 0.951; p < 0.0001). These studies demonstrate that rats with experimental focal glomerulosclerosis treated with CS show an acute, transient reduction in proteinuria; however, chronic (for 16 weeks) CS therapy significantly increases azotemia and results in an increase in glomerulosclerosis and interstitial fibrosis.

Original languageEnglish (US)
Pages (from-to)414-420
Number of pages7
JournalNephron
Volume56
Issue number4
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Cyclosporine
Proteinuria
Fibrosis
Blood Urea Nitrogen
Puromycin Aminonucleoside
Azotemia
Therapeutics
Focal Segmental Glomerulosclerosis
Intraperitoneal Injections
Nephrectomy
Histology
Oils
Blood Pressure
Kidney

Keywords

  • Ciclosporin
  • Glomerulosclerosis
  • Puromycin
  • Rats

ASJC Scopus subject areas

  • Nephrology

Cite this

The effects of ciclosporin in experimental glomerulosclerosis. / Nahman, Norris Stanley; Cosio, F. G.

In: Nephron, Vol. 56, No. 4, 01.01.1990, p. 414-420.

Research output: Contribution to journalArticle

Nahman, NS & Cosio, FG 1990, 'The effects of ciclosporin in experimental glomerulosclerosis', Nephron, vol. 56, no. 4, pp. 414-420.
Nahman, Norris Stanley ; Cosio, F. G. / The effects of ciclosporin in experimental glomerulosclerosis. In: Nephron. 1990 ; Vol. 56, No. 4. pp. 414-420.
@article{30490ab819784e2bacd04bd0cb223537,
title = "The effects of ciclosporin in experimental glomerulosclerosis",
abstract = "The acute and chronic effects of daily, oral ciclosporin (CS) therapy (25 mg/kg) on proteinuria, blood pressure, renal function and histology were studied in rats subjected to unilateral nephrectomy and 3 weekly intraperitoneal injections of the aminonucleoside of puromycin (PAN). PAN therapy resulted in heavy proteinuria by week 4 which declined by weeks 8 and 16. When CS therapy was started several weeks after the last dose of PAN, acute, transient reductions in proteinuria and reversible rises in blood urea nitrogen (BUN) were observed. When CS or oil therapy was started with PAN and continued for 8 or 16 weeks, there were no differences in proteinuria; however, after 16 weeks, CS treated rats had significantly higher BUN levels [65 ± 11 (23.2 ± 3.9) vs. 41 ± 5 mg/dl (14.6 ± 1.8 mmol/l); p = 0.001], a higher percentage of sclerotic glomeruli (47 ± 7 vs. 28 ± 10{\%}; p < 0.0001) and extensive interstitial fibrosis. There was a strong correlation between glomerulosclerosis and extent of interstitial fibrosis (r = 0.951; p < 0.0001). These studies demonstrate that rats with experimental focal glomerulosclerosis treated with CS show an acute, transient reduction in proteinuria; however, chronic (for 16 weeks) CS therapy significantly increases azotemia and results in an increase in glomerulosclerosis and interstitial fibrosis.",
keywords = "Ciclosporin, Glomerulosclerosis, Puromycin, Rats",
author = "Nahman, {Norris Stanley} and Cosio, {F. G.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "56",
pages = "414--420",
journal = "Nephron - Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - The effects of ciclosporin in experimental glomerulosclerosis

AU - Nahman, Norris Stanley

AU - Cosio, F. G.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - The acute and chronic effects of daily, oral ciclosporin (CS) therapy (25 mg/kg) on proteinuria, blood pressure, renal function and histology were studied in rats subjected to unilateral nephrectomy and 3 weekly intraperitoneal injections of the aminonucleoside of puromycin (PAN). PAN therapy resulted in heavy proteinuria by week 4 which declined by weeks 8 and 16. When CS therapy was started several weeks after the last dose of PAN, acute, transient reductions in proteinuria and reversible rises in blood urea nitrogen (BUN) were observed. When CS or oil therapy was started with PAN and continued for 8 or 16 weeks, there were no differences in proteinuria; however, after 16 weeks, CS treated rats had significantly higher BUN levels [65 ± 11 (23.2 ± 3.9) vs. 41 ± 5 mg/dl (14.6 ± 1.8 mmol/l); p = 0.001], a higher percentage of sclerotic glomeruli (47 ± 7 vs. 28 ± 10%; p < 0.0001) and extensive interstitial fibrosis. There was a strong correlation between glomerulosclerosis and extent of interstitial fibrosis (r = 0.951; p < 0.0001). These studies demonstrate that rats with experimental focal glomerulosclerosis treated with CS show an acute, transient reduction in proteinuria; however, chronic (for 16 weeks) CS therapy significantly increases azotemia and results in an increase in glomerulosclerosis and interstitial fibrosis.

AB - The acute and chronic effects of daily, oral ciclosporin (CS) therapy (25 mg/kg) on proteinuria, blood pressure, renal function and histology were studied in rats subjected to unilateral nephrectomy and 3 weekly intraperitoneal injections of the aminonucleoside of puromycin (PAN). PAN therapy resulted in heavy proteinuria by week 4 which declined by weeks 8 and 16. When CS therapy was started several weeks after the last dose of PAN, acute, transient reductions in proteinuria and reversible rises in blood urea nitrogen (BUN) were observed. When CS or oil therapy was started with PAN and continued for 8 or 16 weeks, there were no differences in proteinuria; however, after 16 weeks, CS treated rats had significantly higher BUN levels [65 ± 11 (23.2 ± 3.9) vs. 41 ± 5 mg/dl (14.6 ± 1.8 mmol/l); p = 0.001], a higher percentage of sclerotic glomeruli (47 ± 7 vs. 28 ± 10%; p < 0.0001) and extensive interstitial fibrosis. There was a strong correlation between glomerulosclerosis and extent of interstitial fibrosis (r = 0.951; p < 0.0001). These studies demonstrate that rats with experimental focal glomerulosclerosis treated with CS show an acute, transient reduction in proteinuria; however, chronic (for 16 weeks) CS therapy significantly increases azotemia and results in an increase in glomerulosclerosis and interstitial fibrosis.

KW - Ciclosporin

KW - Glomerulosclerosis

KW - Puromycin

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=0025149433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025149433&partnerID=8YFLogxK

M3 - Article

VL - 56

SP - 414

EP - 420

JO - Nephron - Experimental Nephrology

JF - Nephron - Experimental Nephrology

SN - 0028-2766

IS - 4

ER -